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Abstract 
Plasmacytoid dendritic cells (pDCs) are the most powerful type I interferon (IFN-I) 
producing cells, playing important roles in defense against pathogens, tumor 
immune-surveillance and autoimmune diseases. Therefore, understanding pDC 
regulatory pathways to ultimately manipulate them holds great promise for 
immune-based therapeutics to attenuate several human illnesses. Here we 
investigated the role of Src Family Kinases (SFKs), a family of non-receptor 
tyrosine kinases, in pDC response to toll like receptor (TLR) stimulation. We 
observed for the first time that pDCs from either Fyn or Lyn deficient mice exhibited 
impaired IFN-I and pro-inflammatory cytokine production after TLR7 and TLR9 
stimulation, whereas no difference was observed in conventional DCs. 
Consistently, treatment with either a pan-SFK inhibitor or a selective dual BCR-
ABL/LYN inhibitor (i.e. Bafetinib) profoundly ablated TLR-induced IFN-I production 
in both a human pDC cell line (CAL-1) and in primary pDCs from human peripheral 
blood. Furthermore, genetic ablation of LYN by CRISPR/Cas9 in CAL-1 cells 
resulted in diminished TLR responses. Mechanistically, we showed that the 
inhibition of SFK activity by Bafetinib reduced the TLR-induced activation of 
IKKα/β, ERK1/2, P38 and IRF7, key elements downstream pDC TLR signaling, as 
well as those of MTOR and BCAP, an adaptor protein that bridges PI3K and TLR 
pathways. Taken together, our data indicate that SFKs, particularly LYN, promote 
pDC IFN-I and pro-inflammatory cytokine production and suggest that SFK 
inhibitory drugs, such as Bafetinib, could be considered for attenuating pDC 
response in autoimmune diseases. 
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Riassunto 
Le cellule dendritiche plasmacitoidi (pDCs) sono le cellule che con più potenza 
producono gli interferoni di tipo I (IFN-I), e di conseguenza svolgono un importante 
ruolo nella difesa dai microorganismi patogeni, nell’immuno-sorveglianza dei tumori 
e nello sviluppo delle malattie autoimmuni. Una più profonda conoscenza dei 
percorsi regolatori dell’attivazione delle pDCs potrebbe portare allo sviluppo di 
nuove terapie per alleviare diverse malattie umane. In questo studio, abbiamo 
valutato il ruolo delle tirosin chinasi non recettoriali appartenenti alla famiglia Src 
(SFKs) nell’attivazione delle pDCs in seguito a stimolazione attraverso i recettori 
della famiglia toll-like (TLRs). pDCs ottenute da modelli murini geneticamente 
deficienti per Fyn o Lyn hanno mostrato una ridotta produzione dell’IFN-I e delle 
citochine pro-infiammatorie in seguito a stimolazione attraverso TLR7 e TLR9, 
mentre nessun difetto è stato riscontrato nelle cellule dendritiche convenzionali. In 
aggiunta, sia il trattamento con un inibitore generale delle SFKs che con un 
inibitore selettivo per BCR-ABL e LYN (Bafetinib) hanno profondamente ridotto la 
produzione di IFN-I da parte di una linea cellulare di pDCs (CAL-1) e di pDCs 
derivate dal sangue periferico umano. Ad ulteriore conferma, cellule CAL-1 in cui il 
gene di LYN era stato deleto tramite la tecnologia CRISPR/Cas9 hanno mostrato 
una riduzione nella produzione di IFN-I in seguito a stimolazione. Abbiamo inoltre 
dimostrato che bafetinib agisce riducendo l’attivazione di IKKα/β, ERK1/2, P38 e 
IRF7 indotta dalla stimolazione dei TLRs. Inoltre, anche MTOR e BCAP (una 
proteina adattatrice che collega i pathways di PI3K e dei TLRs) hanno mostrato 
una riduzione della loro attivazione. Pertanto, i nostri dati mostrano come le SFKs, 
e in particolare LYN, promuovano la produzione di IFN-I e citochine pro-
infiammatorie da parte delle pDCs, e suggeriscono che inibitori delle chinasi della 
famiglia SRC, come bafetinib, possono essere considerati per l’attenuazione 
dell’attività delle pDCs nelle malattie autoimmuni. 
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In 1978, Trinchieri and colleagues identified for the first time a subset of 
non-T cell lymphocytes capable of mediating antiviral immune response 
and activate natural killer (NK)-cell-mediated cytotoxicity through the 
production, up to 1000 times higher than any other cell types, of interferon 
(IFN)-α [1]. Those cells were subsequently referred to as natural IFN-
producing cells. However, for long a time they were not better characterized 
because of their rarity and only in 1999 it became clear that these cells 
were an effector cell type of the immune system [2,3], and that actually they 
were the same cell type described for the first time in the 1950s by Lennert 
and Remmele [4], and referred by pathologists as plasmacytoid T cells or 
plasmacytoid monocytes [5]. These cells were ultimately termed 
plasmacytoid dendritic cells (pDCs) due to their ability to mature, acquire 
dendritic cell morphology, present antigens, and stimulate T cells. 
1.1 Plasmacytoid dendritic cells 
1.1.1 Phenotype 
Human pDCs lack the expression of the common lineage markers: CD3, 
CD19, CD14, CD16 and CD56. Moreover, they do not express CD11c, a 
common marker of the myeloid lineage [6]. Instead, they express CD32 (a 
low-affinity Fcγ receptor), CD123 (IL-3 receptor α subunit), CD4, high levels 
of human leukocyte antigen (HLA)-DR and several members of the 
leukocyte immunoglobulin-like receptors (LILR) family, such as LILRA4 
(also known as immunoglobulin-like transcript 7, ILT7) and LILRB4 (or 
ILT3) [3,6,7]. The double positivity of CD123 and HLA-DR has been the 
historical panel of markers used to identify human pDCs. Recently, it has 
been shown that pDCs also selectively express C-type lectin domain family 
4, member C (CLEC4C, also known as blood dendritic cell antigen 2, 
BDCA-2), a C-type lectin transmembrane glycoprotein able to internalize 
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antigens that will be presented to T cells, and Neuropilin 1 (NRP1, also 
known as BDCA-4), a neuronal receptor of the class 3 semaphorin 
subfamily [8]. Thus, just BDCA-2 or BDCA-4 alone can also be used to 
identify human pDCs in peripheral blood and bone marrow. 
LILR family and BDCA-2 and -4 are proteins expressed only by human 
cells and are not expressed on murine pDCs. Consequently, other markers 
are necessary to identify them in mouse. Murine pDCs are defined as 
CD11c intermediate, CD11b-, B220+ and BST2+ [6]. Other markers that can 
be used to identify them are sialic acid-binding immunoglobulin-like lectin H 
(Siglec-H), Ly6C and Ly49Q (also known as killer cell lectin-like receptor 
subfamily A member 17, KLRA17) [6,9]. Of note, although BST2 is fairly 
specific to pDCs and plasma cells in steady-state conditions, it is induced 
on many cell types following exposure to type I and type II IFNs [10]. Also 
Siglec-H expression is mainly confined to pDCs, but it is downregulated 
upon activation [11]. 
1.1.2 Development 
pDCs and classical dendritic cells (cDCs) derive from a common DC 
progenitor (CDP), identified by lack of lineage markers (Lin-), high 
expression of Fms-like tyrosine kinase 3 (FLT3) and macrophage colony-
stimulating factor receptor (M-CSFR) and low levels of c-KIT. FLT3 ligand 
(FLT3L) is the most important cytokine involved in pDC and cDC 
development, controlling the expansion of the common progenitors and the 
peripheral DC homeostasis [12]. Indeed, Flt3l-/- mice showed a reduced 
number of pDCs in the lymphoid organs and bone marrow [13]. Whereas 
Flt3L induces proliferative expansion of CDP, little or no proliferation 
appears to occur during and after pDC commitment [12]. FLT3 signals 
through the activation of signal transducer and activator of transcription 3 
(STAT3), and drives the expression of E2-2, a transcription factor member 
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of the E family and the master regulator of pDC development. Deletion of 
E2-2 in mature pDCs causes the loss of pDC-associated markers and 
generate a cDC-like cell type, with upregulated major histocompatibility 
complex (MHC)-II and increased ability to prime T cells [14]. By contrast, 
the growth factor granulocyte-macrophage colony-stimulating factor (GM-
CSF) activates STAT5 and through the overexpression of the inhibitor of 
DNA binding (ID) 2 inhibits the pDC developmental program activated by 
FLT3. ID2, and also ID3, are members of a family of transcription factors 
that counteract the activity of the E family members sequestering them 
through the formation of heterodimers [14]. 
E2-2 allows the transcription of several proteins involved in the 
development, homeostasis and functions of pDCs, including the 
transcription factors B cell lymphoma 11A (BCL-11A, necessary for the 
expression of IL-7 receptor and FLT3 in early hematopoietic progenitor 
cells), SPIB (important for the differentiation of hematopoietic stem cells 
into pDCs), IFN-regulatory factor 8 (IRF8, essential for pDC and CD8α+ DC 
development since its deficiency results in the absence of pDCs and a 
reduction in the numbers of CD8α+ DCs), Runt-related transcription factor 2 
(RUNX2, necessary for the expression of several pDC-enriched genes, 
among which chemokine receptors CCR2 and CCR5) and class II 
transactivator (CIITA); the cell surface markers BDCA2, ILT7 and Siglec-H; 
and the nucleic acid sensors TLR7, TLR9 and the protein kinase C and 
casein kinase substrate in neurons protein (PACSIN1) [14,15]. 
1.1.3 Sensing of pathogens 
The innate immune system responds to invading pathogens or danger 
signals through the recognition of pathogen-associated molecular patterns 
(PAMPs) or damage-associated molecular patterns (DAMPs). These are 
detected by pattern recognition receptors (PRRs), such as the membrane 
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bound Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) or the 
cytoplasmic retinoic acid-inducible gene (RIG)-I-like receptors (RLRs) and 
nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) 
[16]. 
pDCs are specialized in the recognition of viral pathogens, which sense 
mainly through TLR7 and TLR9, respectively a ssRNA and a dsDNA 
sensor [17] (Figure 1.1). 
 
Figure 1.1: Intracellular TLR signaling. 
Ligand binding to the leucine rich repeats positioned in the extracellular domain of the TLR 
is thought to induce a conformational change that allow the interaction between the TLR TIR 
intracellular domain and MYD88. This adaptor protein, through its N-terminal death domain, 
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interacts with IL-1R associated kinase 4 (IRAK4), which subsequently phosphorylate IRAK1 
and IRAK2. The phosphorylation activates the kinases, which in turn phosphorylate and 
activate TNF receptor-associated factor 6 (TRAF6), an E3 ubiquitin ligase. TRAF6 
associates with UBC13 and UEV1A and polyubiquitin itself and NF-κB essential modulator 
(NEMO, also known as IKKγ). These two polyubiquitin chains are bound by TGF-β activated 
kinase 1 (TAK1)-binding protein 2 (TAB2), which acts as an adaptor protein and brings 
TAB1 and TAK1 near TRAF6 and IKKγ. In this way TAK1 can phosphorylate and activate 
IKKβ, which in turn phosphorylate IκB, leading it to degradation and release of NF-κB. TAK1 
also activates MAPKK3 and MAPKK6, resulting in the activation of JNK, P38 and ERK1/2. 
IRAK1 can also interact with TRAF6, TRAF3, IKKα, osteopontin (OPN), leading to IRF7 
phosphorylation and its translocation to the nucleus [18,19]. 
Figure from “Intracellular Toll-like receptors” by A. L. Blasius, 2010 [18]. 
TLR7 and TLR9 reside in the endoplasmic reticulum (ER), but they 
encounter their ligands only in the endosomal compartment. This trafficking 
is mediated by Unc-93 homolog B1 (UNC93B1), a residing ER protein 
which directly interacts with the transmembrane domain of intracellular 
TLRs and mediates their translocation from ER to endolysosomes [20]. 
Viruses and endogenous nucleic acids end up in the endosomal 
compartments through endocytic or phagocytic events. Hepatitis A virions 
enter pDCs bound to T cell immunoglobulin and mucin domain-containing 1 
(TIM1) receptors [21], whereas hepatitis C virus through via exosomes 
released by infected cells [22]. When bound to antibodies, viruses and 
nucleic acids can enter pDCs through Fc receptors, such as FcγRIIA and 
FcγRIIB [23–25]. Also Siglec-H and BDCA-2 have been shown to play a 
role in the antigen uptake [11,26]. Instead, the internalization of large DNA-
immunocomplex requires the convergence of the phagocytic and 
autophagic pathways, a process called microtubule-associated protein 
1A/1B-light chain 3 (LC3)-associated phagocytosis (LAP), which involved 
autophagy-related proteins, but not the conventional autophagic 
preinitiation complex [27]. Irrespective of the route of entrance, the 
encounter of TLRs with their ligands results in the activation of these 
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receptors, leading to type I IFN (IFN-I) production via the myeloid 
differentiation primary response protein 88 (MYD88)-IRF7 pathway and to 
pro-inflammatory cytokine production via MYD88-nuclear factor-κB (NF-κB) 
pathway (Figure 1.1) [17,18], but which pathway is activated depends on 
the endosomal maturation. CpG-A oligonucleotides (ODNs), a synthetic 
TLR9 agonist, aggregate and form multimeric particles in the early 
endosomes, which activate the MYD88-IRF7 pathway and consequently 
induce IFN-I production. Instead, CpG-B ODNs remain in a monomeric 
state and thereby are transferred quickly to late endosomes, where they 
trigger the MYD88-NFκB pathway and pro-inflammatory cytokine 
production [28] (Figure 1.2). 
 
Figure 1.2: Signaling of CpG ODN classes in different endosomal 
compartments. 
Figure from “Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and 
autoimmune diseases”, by M. Gilliet, 2008 [17]. 
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Although the TLR-mediated detection of invading pathogens elicits the 
strongest activation, pDCs can also sense replicating viruses in the 
cytoplasm through RIG-I, a member of the RLR family, and consequently to 
initialize a TLR-independent IFN-I production [29]. 
1.1.4 Regulation of TLR response: surface receptors 
The regulation of the amplitude of the IFN-I production and, more generally, 
of the pDC activation state in response to TLR7 and 9 ligands is an 
important step, since dysregulation of this response can lead to either a 
defective immune response to pathogens and tumoral cells or 
autoimmunity [30–33]. Thereby, pDCs express on their surface several 
receptors capable to influence pDC activation [17]. These receptors usually 
either contain or couple with an adaptor protein that contain intracellular 
tyrosine-based activation motif (ITAM) or intracellular tyrosine-based 
inhibitory motif (ITIM), and the tyrosine in these sequences, once 
phosphorylated, acts as docking site for different proteins, leading to the 
activation of different pathways [17]. 
Human and mouse pDCs express DNAX activation protein 12 (DAP12) and 
the γ-chain of Fcε receptor (FcεRIγ), two ITAM-containing adapter proteins 
present at the cell membrane which associate with other surface receptors 
in order to transmit their signals. In human, DAP12 associates with NKp44 
[34], an IL-3-induced receptor that after engagement inhibits pDC IFN-α 
production, whereas in mouse it couples with Siglec-H [35], again 
transmitting into the cell a signal that inhibits the TLR-mediated activation. 
Up to now, there are not any receptors known to associate with FcεRIγ in 
murine pDCs. However, it is different on the surface of human pDCs. 
BDCA-2 associates with FcεRIγ and they potently suppress the induction of 
IFN-I production after antigen capture, presumably by a mechanism 
dependent on calcium mobilization [8,36]. Also ILT7 decreases the TLR-
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mediated pDC activation using the ITAM on FcεRIγ, again presumably 
through a similar mechanism [7,37]. Interestingly, the ligand of ILT7 is bone 
marrow stromal antigen 2 (BST2, also known as tetherin), a lipid raft 
associated protein with anti-viral property which is expressed mainly in 
response to IFN-I stimulation, suggesting its involvement in a negative 
feedback loop to  tune the IFN-I production [37]. FcεRIγ can also associate 
with another member of the CLR family, the DC immunoreceptor (DCIR), 
leading to the inhibition of the TLR9-induced IFN-α production after ligand 
engagement [38]. The inhibition of pDC activation can be mediated also by 
immunoglobulin, which are detected by FcεRIα and FcγRIIB, suggesting an 
important mechanism by which the potentially deleterious effects of IFN-I 
are prevented during a secondary infection [23]. Finally, dual CD300a/c 
triggering by crosslinking antibody reduced TNF-α and increased IFN-α 
secretion by pDCs [39]. However, the signaling events responsible for such 
effect remain to be determined, given that CD300c contains 3 ITIMs 
whereas CD300a has a short intracellular domain with a charged amino 
acid in the transmembrane domain, which may allow the association with 
signaling adapters as DAP12 and FcεRIγ [39]. 
Conversely, not many ITIM-containing receptors have been identified on 
pDC surface, and just few of them have been characterized. Ly49Q, a C-
type lectin-like membrane glycoprotein, is highly express on murine pDCs 
and its binding with H-2Kb, an MHC-I molecule, is essential for the IFN-α 
and IL-12p70 production after TLR stimulation [40,41], regulating the 
cytoskeletal architecture and the spatiotemporal trafficking of TLRs [9,42]. 
Although counterintuitive, all these striking evidences support a positive 
regulation of TLR signaling by ITIMs and a negative regulation by ITAMs, 
suggesting that pDCs evolved a peculiar way to exploit these pathways 
different from other immune subsets, maybe with the purpose to counteract 
an easy hijacking of the immune response by microbial and viral proteins. 
The importance of tyrosine phosphorylation for the pDC activation has been 
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recently suggested again in a study by Bunin et al., where they showed that 
the absence of the receptor protein tyrosine phosphatase sigma (PTPRS) 
in human and of Ptprs and Ptprf, an homologous receptor phosphatase, in 
mice enhances IFN-I and TNF-α production [43]. 
1.1.5 Regulation of TLR response: intracellular molecules 
In addition to the surface receptors, several intracellular molecules capable 
to influence the TLR7 and 9 signaling have been identified in pDCs. 
SCARB2, a scavenger receptor, and phopsholipid scramblase 1 (PLSCR1) 
are two proteins regulating TLR9 endosomal translocation and, 
consequently, they influence IRF7 nuclear translocation and IFN-I 
production [44,45]. Protein kinase C and casein kinase substrate in 
neurons protein 1 (PACSIN1) and dedicator of cytokinesis 2 (DOCK2) are 
endocytic adaptors which are necessary for the induction of IFN-I, but not 
of pro-inflammatory cytokines, after TLR9 stimulation, likely because of 
their role in the reorganization of the cell cytoskeleton [46,47]. Also Viperin, 
an IFN-I inducible antiviral protein, favors only IFN-I production, recruiting 
IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated 
factor 6 (TRAF6) near the TLRs and inducing IRF7 nuclear translocation 
[48]. Lastly, Bruton’s tyrosine kinase (BTK) affects in a negative way TLR9, 
but not TLR7, signaling, although the mechanism is not clear [49]. 
A special mention in the regulation of the TLR-mediated pDC activation is 
due to the phosphatidylinositol-3 kinase (PI3K)-protein kinase B (PKB, also 
known as AKT)-mammalian target of rapamicin (MTOR) pathway. Inhibition 
of PI3K, MTOR or the downstream kinases p70 ribosomal s6 kinases 
p70S6K1 and p70S6K2 blocked the interaction of TLR9 with the adaptor 
MYD88 and the subsequent activation and nuclear translocation of IRF7, 
resulting in impaired IFN-I and TNF-α production [50–52]. The importance 
of the PI3K-AKT-MTOR pathway in the tuning of pDC activation is due to 
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the multitude of signals that can regulate it, thereby allowing to a series of 
factors not strictly related with the immune system, as the cell energy level, 
the hypoxia status, the cellular stress, the DNA damage, to influence the 
TLR-mediated activation (Figure 1.3). 
 
Figure 1.3: Regulators of PI3K-AKT-MTOR pathway. 
Figure from “Immunoregulatory functions of MTOR inhibition”, by A.W. Thomson 2009 [53]. 
Although it is not clear how TLR7 and TLR9 can lead to the activation of the 
PI3K pathway in pDCs, it has been recently suggested a role for the B-cell 
adaptor of PI3K (BCAP), since it is highly expressed in pDCs and in 
macrophages it has been shown to be able to interact with MYD88, through 
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a N-terminal TIR homology domain, and with PI3K, through a 
phosphorylated tyrosine which binds the SH2 domain of the regulatory 
subunit (p85) of PI3K [54,55]. 
1.1.6 pDCs and viral infections 
As consequence of the PRRs primarily expressed, pDCs are mainly 
equipped to respond to viral pathogens. 
During acute viral infection, pDC IFN-I production is primarily important 
during the early phase, whereas later on other cell types, such as 
macrophages and epithelial cells, become the most relevant source, mainly 
because they overcome pDCs in number [56]. In addition, also the route of 
infection is important, since the IFN-I production by pDCs is important 
during systemic infection, but only secondary during local viral infection 
[57]. Noteworthy, pDC responses to acute viral infections could be not 
always beneficial: excessive production of IFN-I during influenza virus 
infection can result in damage of bronchial epithelium as consequence of 
uncontrolled inflammation and cellular apoptosis mediated by TNF-related 
apoptosis-inducing ligand (TRAIL) [58]. 
The role of pDCs during chronic viral infection has been principally studied 
in the context of HIV. pDCs can sense HIV through TLR7, activating IFN-I 
production and trafficking to peripheral lymph nodes and gut mucosa. 
However, since HIV stimulated pDCs express low levels of maturation 
molecules, induce a weak T cell response and produce continuously IFN-I, 
it has been proposed that they may contribute to the chronicity of HIV 
infection [59]. Indeed, increased IFN-α expression in circulating peripheral 
blood mononuclear cells (PBMCs) correlates with HIV disease progression, 
and especially the IFN-α2b subtype is upregulated in HIV patients during 
the course of the disease [60]. Although this seems counterintuitive, since 
IFNs are the most important antiviral mediators and are capable to reduce 
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viral replication through the induction of a whole set of antiviral genes, it is 
not surprising. Indeed, it is precisely because of their importance as 
mediators of the antiviral response that current viruses needed to find a 
way to skew IFN-I activity in their favor to survive. For example, HIV takes 
advantage of the INF-α-mediated upregulation of TRAIL on uninfected 
CD4+ T cells, which leads them to apoptosis and contributes to their wane 
and to the destruction of lymph node architecture, and of p53, which favors 
the apoptosis of virally infected cells [59]. 
During chronic HIV infection, circulating blood pDCs have diminished 
functionality in response to TLR7 and TLR9 stimulation [61,62]. This 
compromised functionality is thought to occur because of a greater 
refractoriness to stimulation, since they are exposed to HIV, bacterial DNA 
(as a consequence of the increased gut permeability) and inflammatory 
cytokines. Lastly, it is important to mention that HIV stimulated pDCs can 
also suppress the immune response through the non-canonical activation 
of NF-κB, which causes IDO expression and T reg cells induction [63]. 
The beneficial or detrimental effects of IFN-I in chronic viral infection 
depends also by the timing of action. It has been shown in SIV infection 
that exogenous administration of IFN-α2a early on increases the 
expression of antiviral genes and prevents systemic infection, whereas a 
continuous IFN-α2a treatment induces an IFN-I desensitization, leading to a 
decrease in the antiviral gene expression and to an increase in the viral 
load and in the loss of CD4+ T cells [64]. The importance of the time when 
the IFN-I is produced has been also confirmed in a mouse model. pDC 
ablation, or just the loss of their ability to signal through TLR7, seems to 
have a negative effect on T cell priming and viral clearance [65,66]. Indeed, 
early administration of exogenous IFN-I prevents lymphocytic 
choriomeningitis virus (LCMV) infection. However late administration has 
no effects, and, actually, the blockade of IFN-I signaling throughout the 
infection improves T cell function and diminishes viral burden [67–69]. 
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1.1.7 pDCs and autoimmunity 
Considered the ability to produce high amount of IFN-I, pDCs have been 
suggested to play a role in the pathogenesis of autoimmune diseases that 
are characterized by IFN-I signature. Among these, the most important in 
term of prevalence is systemic lupus erythematosus (SLE), and always 
more compelling evidence are suggesting a role for pDCs in the onset of 
the disease. 
SLE is a chronic disease of variable severity with a waxing and waning 
course, with significant morbidity that can be fatal in some patients [70]. 
The etiology of SLE includes genetic, epigenetic and environmental 
components, with female hormonal factors strongly influencing the 
pathogenesis. These factors lead to an irreversible break in immunological 
tolerance manifested by immune responses against endogenous nuclear 
antigens [71,72] (Figure 1.4). 
Figure 1.4: Pathogenesis of systemic lupus erythematosus. 
Increased production of auto-antigens during apoptosis (UV-related and/or spontaneous) 
followed by a decreased disposal of these antigens by monocytes/macrophages and a 
deregulated internalization and presentation by antigen presenting cells, are important steps 
for the initiation of the autoimmune response. Apoptotic bodies, containing danger elements 
that can bind PRR as nucleosomes, are internalized by DCs and B cells through Fc 
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receptors and BCR and drive the production of IFN-I and auto-antibodies, respectively. 
Moreover, antimicrobial peptides released by damaged tissues such as LL37 may bind 
nucleic acids, inhibiting their degradation and facilitating their endocytosis by antigen 
presenting cells, as pDCs, thereby stimulating IFN-I production. Immune complexes and 
complement activation pathways mediate tissue injury, since the failure to clear immune 
complexes results in tissue deposition and consequent injury, mediated by the recruitment of 
inflammatory cells, reactive oxygen intermediates, production of inflammatory cytokines, and 
modulation of the coagulation cascade. Locally produced cytokines, such as IFN-α and 
tumor necrosis factor (TNF), contribute to affected tissue injury and inflammation. 
Figure from “Systemic Lupus Erythematosus: Pathogenesis and Clinical Features.”, by G. 
Bertsias 2012. 
In patients with SLE, pDCs are continuously activated by circulating 
immune complexes composed by antibodies bound to self DNA and 
nucleoproteins, which are internalized by Fc receptors and translocated to 
endosomal compartment where they encounter TLRs [73]. It is important to 
note that in non-pathological conditions, antibodies bound to DNA and 
nucleoprotein alone are unable to protect extracellular DNA fragments from 
the activity of nucleases, as a consequence of the immune system efforts 
to impede the recognition of self DNA and RNA. However, in autoimmune 
disease as SLE several host factors, such as LL37 and high-mobility group 
box 1 (HMGB1), have been implicated in the nullification of these efforts 
and in the conversion of self DNA into triggers for pDC activation. LL37 is 
an antimicrobial peptide able to bind self-DNA fragments released by dying 
cells, forming large aggregates which block the degradation mediated by 
extracellular nucleases [74]. In addition, the LL37-self-DNA aggregate is 
retained longer in the early endosomes of pDCs, where TLRs trigger IRF7 
pathway [74]. HMGB1 is a nuclear DNA binding protein that is released by 
dying cells. It binds only multimeric DNA aggregates, and subsequently 
HGMB1-DNA complexes bind the receptor for advanced glycation end-
products (RAGE) on the pDC surface, entering the cells and potently 
enhancing IFN-I production [75]. The continuous synthesis of IFN-I induces 
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the activation and the maturation of DCs, which consequently stimulates 
and activates autoreactive T cells. In addition, IFN-I, combined with IL-6, 
stimulates the differentiation of autoreactive B cells into autoantibody-
secreting plasma cells [72]. 
Studies in SLE murine models have showed that genetic deficiency or 
antibody blockade of the IFN-I receptor reduced serologic, cellular, and 
histologic disease manifestations and extended survival [76,77], confirming 
that IFN-I is essential to the disease pathogenesis. SLE murine models 
have also allowed to prove definitively the important role of pDCs in the 
onset of the disease. Mice lacking the IFN regulatory factor 8 (IRF8), and 
therefore lacking pDCs, or carrying a mutation affecting the 
peptide/histidine transporter solute carrier family 15, member 4 (SLC15A4), 
which turn off the TLR7/9-mediated pDC cytokine production, show almost 
complete absence of anti-nuclear, anti-chromatin, and anti-erythrocyte 
autoantibodies, along with reduced kidney disease [78]. However, it is fair 
to note that IRF8 is not essential only for pDC development and that 
SLC15A4 seems to be necessary also for TLR7-induced production of 
antibodies by B cells. Recently, three other studies with cleaner models 
have strongly proved the involvement of pDCs in the SLE onset. The first 
study exploited global or CD11c-specific E2-2 haplodeficiency, which 
impairs the development of pDCs but not B cells, in lupus prone mice and 
they observed an abolition of the key disease manifestations, including anti-
DNA antibody production and glomerulonephritis [79]. The second and the 
third studies used lupus-prone mice in which pDCs can be selectively 
depleted in vivo through the diphteria toxin administration, and they showed 
that an early, transient ablation of pDCs, before disease initiation, resulted 
in reduced splenomegaly and lymphadenopathy, impaired expansion and 
activation of T and B cells, reduced antibodies against nuclear autoantigens 
and improved kidney pathology [80,81]. Taken together, these studies 
validate the role of pDCs in the onset of SLE, and they also suggest that 
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pDCs could be considered as disease target. 
1.1.8 pDCs and tumors 
pDCs have been characterized in a variety of human neoplasms, including 
carcinomas from different sites, melanoma, and hematopoietic 
malignancies [82]. Moreover, their presence has also been documented in 
tumor draining lymph nodes [83]. Although the clinical benefits of IFN-I 
administration to cancer patients have been shown [84], the presence of 
tumor-associated pDCs (TA-pDCs) is often associated with poor prognosis, 
since they tend to be tolerogenic rather than immunogenic. This 
polarization could depend to the alternative activation of TA-pDCs, which 
drives the expression of inducible T-cell co-stimulatory ligand (ICOSL) and 
the production of the immunosuppressive enzyme IDO. The expression of 
ICOSL on pDCs seems to correlate with breast cancer progression, as a 
consequence of the amplification of IL-10 production by T reg cells [85]. 
Also the IDO overexpression has been associated with worse clinical 
outcome in patients with breast carcinomas, and this because TA-pDCs in 
breast cancer are poor producers of IFN-I, favoring instead the expansion 
of T reg cells [86]. An additional tolerogenic mechanism proposed for pDCs 
is based on the secretion of granzyme B, which, in combination with IL-3 
and IL-10, is capable to block T cell proliferation [87]. 
However, it is important to note that pDCs can still also promote 
immunogenic antitumor response, if appropriately triggered. Indeed, the 
injection of pDCs previously activated and loaded with tumor-associated 
antigens into metastatic melanoma patients leads to improvement in the 
CD4+ and CD8+ T cell response [88]. It has also been observed in an 
orthotopic murine mammary tumor model that intratumoral administration of 
TLR7 agonist results in a TA-pDCs activation with potent antitumoral 
effects [89]. Moreover, the administration of Imiquimod, a TLR7 agonist, to 
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a mouse model of melanoma in which the mice are injected with C57BL/6-
derived B16 melanoma cell line, stimulates pDCs and mediate tumor 
regression through the expression of TRAIL and granzyme B and the 
activation of NK cells [90,91]. 
These data indicate that vaccination strategy using activated pDCs may be 
an attractive therapeutic strategy to overcome immune tolerance in certain 
types of cancer. 
Up to now, many immune functions of pDCs have been described; 
however, there are still a lot of questions about their complex biology that 
need to be answered. With the recognition of pDC involvement in human 
pathologies, it became primarily important to increase our knowledge on 
pDCs biology, especially on how their immune activity is regulated, in order 
to find new therapeutic strategy for many of the disease scenarios 
discussed above. 
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1.2 Src Family Kinases 
Src family kinases (SFKs) are non-receptor tyrosine kinases that are 
involved in several cellular process, as cytoskeletal assembly [92], cell-cell 
and cell-matrix interaction [93], DNA replication [94], cell survival and 
proliferation [95], cellular response to external stimuli [96]. 
This family is composed of nine members, but only eight of them are 
expressed in mammalian cells: Fyn, Src and Yes are expressed widely 
throughout the organism, whereas Blk, Fgr, Hck, Lck and Lyn are 
expressed only by the hematopoietic system [97]. 
All SFKs share a common structure [97,98]. At the N-terminal there are a 
glycine (position 2) and a cysteine (position 3) that function as acceptor 
sites for the addition of myristate and palmitate (palmitoylation does not 
occur on Blk and Src) [97,98]. These post-translational modifications 
promote association with the lipids in the membrane, especially at the level 
of the lipid rafts, and this association is essential to bring the kinases in 
contact with the receptors and the membrane proteins that are their 
substrates [97,98]. Then, there is an N-terminal unique domain, the less 
understood part of SFKs and the only part that highly differs among the 
family members, thereby it has been suggested to confer specificity. Src-
homology 3 (SH3) domain and Src-homology 2 (SH2) domain follow the 
unique domain [97,98]. SH3 is a sequence of 40-70 aminoacids that 
recognizes proline-rich motif, and it can be found on a wide variety of 
proteins, where it favors the interaction among proteins. The solving of the 
SH3 domain by crystallography and nuclear magnetic resonance 
spectroscopy revealed a clasped hands interaction, whereby the proline-
rich motif assumes a particular helical appearance and interdigitates with 
pockets and a salt bridge in the SH3 domain [99]. Instead, SH2 domain 
consists of about 100 aminoacids and recognizes with high affinity 
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particular sequences bearing a phosphorylated tyrosine [97,98]. Following, 
there is the catalytic domain, which moves a phosphate group from ATP to 
the substrate tyrosine [97,98]. Lastly, is the C-terminal regulatory domain. 
The SFK activity is regulated by two phosphorylations at two different sites 
[98,100,101]. With regard to Lyn, the phosphorylation at tyrosine 397, 
positioned into the activation loop of the kinase domain, has an activating 
effect, whereas the phosphorylation at tyrosine 508, in the C-terminal 
negative regulatory domain, causes a conformational change that closes 
the enzyme in an inactive form. The inhibitory phosphorylation is mediated 
by carboxy terminal Src-kinase (CSK), whereas the activating 
phosphorylation is, actually, an auto-phosphorylation mediated by the SFK 
itself. Instead, the inhibitory phosphorylation is removed by Protein tyrosine 
phosphatase, receptor type, C (PTPRC, also known as CD45), whereas the 
activating phosphorylation can be removed by Protein tyrosine 
phosphatase, non-receptor type 22 (PTPN22) and PTPN6 [102] (Figure 
1.5). 
Figure 1.5: A model for SFKs activation 
A: Intramolecular interactions involving SH2 and SH3 domains restrain SFKsin a closed 
conformation. In this state, an inhibitory conformation of the activation loop helps disrupt the 
kinase active site by interfering with substrate. In addition, the A loop helix protects Tyr-416 
from phosphorylation. B: The dephosphorylation of C-terminal tyrosine or the competitive 
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binding of optimal SH2/SH3 domain ligands, allows the kinase domain to open, disrupting 
the A loop helix and exposing Tyr-416 to phosphorylation. C: The auto-phosphorylation at 
Tyr-416 causes a conformational changes that reorganizes the activation loop, relieving the 
steric barrier for substrate binding and reconstituting a fully active tyrosine kinase. 
Figure from “Crystal Structures of c-Src Reveal Features of Its Autoinhibitory Mechanism”, 
by W. Xu 1999 [101]. 
The complexity of the SFKs and their interactions with so many proteins 
related to signal transduction and cellular function place them into a very 
important position for the regulation of cell proliferation, differentiation, 
survival, metabolism, and other essential functions of the cells. One of the 
critical roles of SFKs is to regulate the inflammatory response. 
1.2.1 SFKs and activating pathways 
The engagement of the prototypical activating immunoreceptor leads to the 
SFK activation, with consequent phosphorylation of the ITAM. This motif, 
which the consensus sequence is YxxI/Lx(6-12)YxxI/L, is present in the 
cytoplasmic tail of the activating immunoreceptor. Some immunoreceptors 
do not encode an ITAM, but instead they bear a positively charged 
transmembrane aminoacid, which mediates association with negatively 
charged transmembrane residues of ITAM-containing associate proteins, 
as the CD3γ/δ/ε chains for T cell receptors, the Igα/β chains for B cell 
receptors, the FcRγ chain for Fc receptors and DAP-12 for activating NK 
receptors [103]. The activation of SFKs is mediated by CD45, which de-
phosphorylates the tyrosine in the C-terminal end [97,98]. Although the 
mechanism is not completely clear, the SFKs localization into the lipid rafts 
[104,105] and the fact that the disruption of the raft structures by 
pharmacological cholesterol depletion strongly reduces signaling [96,106], 
lets us suppose that this interaction takes place within the lipid rafts. In 
addition, the engagement of the immunoreceptor with its ligand causes a 
conformational change that favors the receptor complex dislocation into the 
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raft and, as a consequence of the kinase activation and the proximity with 
the immunoreceptor, the associate proteins undergo tyrosine 
phosphorylation into the ITAM sequences [97,98]. This leads to the 
recruitment of other kinases, usually spleen tyrosine kinase (Syk) or Zeta-
chain-associated protein kinase 70 (Zap-70), which use the phosphorylated 
tyrosines in the ITAM sequences as docking sites for their SH2 domains 
[97,98]. The binding, and also another phosphorylation mediated by the 
SFKs [107,108], activates the kinases, which in turn phosphorylate various 
other scaffold proteins, such as linker of activated T cells (LAT), B cell 
linker (BLNK), lymphocyte cytosolic protein 2 (SLP-76) [97,98]. These 
proteins are the base from which the different pathways begin, leading to 
changes in cell morphology, transcriptional activity, proliferation, cytokine 
secretion and antibody secretion in lymphocytes or phagocytosis and 
degranulation in myeloid cells (Figure1.6). 
 
Figure 1.6: Activating signaling pathways utilizing ITAM-containing adapters. 
“Classical immunoreceptors” refers to those signaling molecules that are directly couples to 
ITAM adapters FcRγ or DAP12 through transmembrane charged residues. To the right are 
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shown examples of receptors that link to or co-opt the ITAM pathway, as leukocyte integrins. 
For all these receptors, it remain unclear how they are coupled to the ITAM adapters. 
Despite the difference in the coupling of these receptors to the adaptor proteins, the overall 
signaling events that follow receptor engagement by their respective ligands are similar, and 
as first step expects SFKs activation and phosphorylation of ITAM, leading to docking sites 
for Syk/Zap70 kinases. 
Figure from “Src-family and Syk kinases in activating and inhibitory pathways in innate 
immune cells: signaling cross talk”, by C. A. Lowell 2011 [109]. 
1.2.2 SFKs and inhibitory pathways 
Negative regulators in the form of receptors bearing one or more ITIM, 
whose consensus sequence is S/I/V/LxYxxI/V/L, are employed by the 
immune system [110]. Ligand engagement by these receptors results in 
ITIM phosphorylation by SFKs and recruitment of phosphotyrosine 
phosphatases (PTP) such as Protein Tyrosine Phosphatase, Non-Receptor 
Type 6 (PTPN6, also known as SHP-1) and PTPN11 (also known as SHP-
2), or the inositol polyphosphate-5-phosphatase (INPP5, also known as 
SHIP-1). The PTP recruitment results in dephosphorylation of activation 
pathway effectors, as those described before [111,112], whereas SHIP-1 
recruitment results in the prevention of calcium signaling and protein kinase 
C activation through the dephopshorylation of the phospholipase C 
substrate: phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [112]. 
The realization that SFKs play an important role in the activation of 
inhibitory signaling was reached during studies with Lyn-/- mice. These mice 
show a peculiar phenotype, with hyper-responsive B cells, increased Ig 
levels and autoimmunity, as a consequence of an exaggerated activating 
response due to a reduced phosphorylation of ITIM-containing receptors 
[113,114]. In addition, Lyn-/- mice lose also an important inhibitory loop used 
to control the SFK activity in the activating pathways: phosphorylation of 
phosphoprotein membrane anchor with glycosphingolipid microdomains 1 
(Pag, also known as Cbp) by SFKs results in the recruitment of Csk to the 
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lipid rafts, which in turn phosphorylates and helps to inactivate the kinases 
[115]. In Lyn-/- mast cells, the decreased activity of Csk on Fyn results in the 
hyperactivation of the Gab2/PI3K pathway and subsequent increased 
degranulation [115]. 
Other than Lyn, also Fgr has been shown to be implicated in negative 
regulation, since Fgr-/- macrophages show an increased rate of uptake of 
IgG-coated red cells [116,117] (Figure 1.7). 
 
Figure 1.7: Inhibitory signaling pathways utilizing ITIM-containing adapters. 
To the left are classical inhibitory receptors that contain ITIM binding sequences within their 
cytoplasmic tails. Inhibitory receptors are often engaged simultaneously with activating 
receptors, though they recognize distinct sets of ligands. The ITIM domains on these 
proteins are then phosphorylated by SFKS, which results in the recruitment of tyrosine or 
lipid phosphatase. To the right are shown examples of inhibitory receptors that functions 
through “inhibitory” ITAM signaling. This pathway is believed to be engaged following low 
avidity interactions of these receptors with various ligands, which results in only weak 
phosphorylation of associated ITAM adapters. The partial phosphorylation of the ITAMs 
leads to SHP1/2 recruitment instead of Syk, hence engaging an inhibitory response 
analogous to an ITIM pathway. 
Figure from “Src-family and Syk kinases in activating and inhibitory pathways in innate 
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immune cells: signaling cross talk”, by C. A. Lowell 2011 [109]. 
1.2.3 SFKs and other pathways 
The importance of SFKs is not limited to the immunoreceptors. There are 
several other pathways, within the immune system that exploit this kinase 
family. 
SFKs have been implicated in the downstream signaling of chemokine G 
protein coupled receptors (GPCRs). In macrophages, both C-X-C 
chemokine receptor type 4 (CXCR4) and C-C chemokine receptor type 5 
(CCR5) activate MAPK and PI3K pathways through Lyn [118,119]. Also 
CCR2 and CXCR1 have been shown to require SFK activity for the full 
activation of their signaling [120,121]. In neutrophils, the combined absence 
of Hck and Fgr causes a functional defect following formyl peptide 
stimulation, which signals through GPCR coupled formyl peptide receptor 
[122]. 
Several GPI-linked proteins in innate cells, such as CD14 and plasminogen 
activator receptor (uPA-R), signal through tyrosine phosphorylation 
mediated by SFKs [123]. 
The study of knockout mice has underlined also a role for the SFKs in the 
immune cell integrin signaling. Hck- or Fgr-deficient neutrophils show 
normal response to the crosslinking of β2 and β3 integrins. However, double 
and triple knockout (Hck-/-Fgr-/-Lyn-/-) neutrophils have impaired migration 
and adhesion [124]. In addition, macrophages from these mice fail to 
rearrange their actin cytoskeleton when exposed to an extracellular matrix 
protein-coated surfaces, due to a reduced phosphorylation of the E3 
Ubiquitin Protein Ligase c-Cbl and the subsequent reduced recruitment of 
PI3K p85 subunit to the plasma membrane [125]. 
Other than integrins, also selectins are dependent on the SFK activity. 
Recognition of E-selectin by leukocyte P-selectin glycoprotein ligand-1 
(PSGL-1) and CD44 leads to the tyrosine phosphorylation that are inhibited 
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by SFK specific inhibitors [126,127]. In this signaling response, Fgr seems 
to play the dominant role [127]. 
1.2.4 Activation and inhibition:- beyond the nomenclature 
Unfortunately, the biology of the immunoreceptors is more complex than 
described. Indeed, we are now beginning to appreciate how ITAM can 
mediate inhibition and ITIM can mediate activation. 
The first evidence about inhibitory ITAM came out from the study of the IgA 
signaling. For a long time it has been known that, in the absence of the 
antigen, monomeric IgA exert anti-inflammatory effects (downregulating 
IgG mediated phagocytosis, oxidative respiratory burst and cytokine 
release) whereas. multimeric IgA complexes, formed by several monomeric 
IgA aggregated with their antigen, exert a pro-inflammatory effect [128]. 
Although also other Ig isotypes can mediate inhibitory signals exploiting 
ITIM-bearing receptors to fulfill this purpose, no ITIM-bearing IgA receptors 
have been identified. Lately, this mechanism has been elucidated, and it 
has been shown that both the monomeric-inhibition and the multimeric-
activation needs tyrosine phosphorylation of FcRγ, the ITAM-containing 
adaptor receptor of the IgA receptor FcαRI [129]. The trick is that 
monomeric-inhibition induces weakly the phosphorylation of the ITAM and 
allows the recruitment of both SHP-1 and Syk, whereas the multimeric-
activation induces strongly the phosphorylation and results only in Syk 
recruitment [129]. This positive/negative regulation of the immune cells 
mediated by an high/low intensity stimulation of the Fc receptor associated 
with FcRγ has also been extended to IgE and FcεRI [130]. In pDCs, several 
surface receptors, as BDCA-2 and ILT7, exploit FcRγ to transmit inhibitory 
signals to the cell, as previously described [7,36]. 
The ITAM-containing adaptor protein DAP12 associates with several 
surface receptors to transduce their activating signals. However, DAP12 
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deficient macrophages produce higher amounts of pro-inflammatory 
cytokines in response to various TLR and FcRγ receptor stimulations, 
suggesting the existence of an inhibitory DAP12 signaling [131]. 
Noteworthy, this DAP12-dependent inhibition appears to be macrophage 
specific, since DAP12-deficient dendritic cells do not respond stronger to 
stimulation [131]. Also several pDC surface receptors, as Siglec-H and 
NKp44, exploit DAP12 to transmit inhibitory signal to the cell, as previously 
described [34,35]. 
Interestingly, an hidden ITIM is encoded in DAP12 ITAM, exactly on the 
first tyrosine of the consensus sequence (spYqeLqgqrsdvYsdL, uppercase 
the aminoacids for the consensus ITAM, underlined the aminoacids for the 
consensus ITIM). Whether this hidden ITIM can recruit inhibitory 
phosphatase is still unknown. 
As ITAM does not transmit only activating signals, ITIM does not transmit 
only inhibitory signals. 
The ITIM-containing protein TREM-like transcript-1 (TLT1) is present in the 
granules of resting platelets and its expression on the surface membrane 
increases after activation. Through its ITIM, TLT1 can recruits SHP-2 and 
enhance FcεRI-mediated calcium signaling [132]. 
On murine pDCs, the ITIM-containing receptor Ly49Q has been shown to 
be essential for the cell activation after TLR stimulation [40]. 
Therefore, several receptors on pDC surface exploit ITAM and ITIM 
sequences to signal and regulate pDC immune activity, suggesting a role 
for SFKs in the pDC biology.  
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2. Aim of the work 
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Plasmacytoid dendritic cells are the most powerful interferon type I (IFN-I) 
producers among the immune cell subsets. As a consequence of this 
peculiar ability, they play important role in the defense against pathogens, 
tumor immune-surveillance and autoimmune diseases. Since both a 
reduction and an increase in the IFN-I production by pDCs influence 
negatively the immune response and can lead to immune-pathologies, 
pDCs have evolved a complex system to modulate their activation status. 
Understanding this tuning and ultimately manipulate it holds great promises 
for immune-based therapeutics to attenuate several human illnesses. Up to 
now, it has been shown that several receptors on the surface of pDCs can 
modulate the cytokine production TLR-mediated, but the downstream 
pathway that they activate is still unclear. Although, it has been shown that 
their signaling often start from an immunoreceptor tyrosine-based activation 
motif (ITAM) or immunoreceptor tyrosine-based inhibition motif (ITIM). 
Given that phosphorylation of ITAM and ITIM is often mediated by SFKs, a 
family of non-receptor tyrosine kinases, we decided to investigate the role 
of SFKs in pDCs biology. To evaluate the SFKs involvement in the pDC 
activation, we exploited mouse and human genetic models of SFK 
deficiency and we assessed the ability of pDCs to respond to TLR 
stimulation by different techniques. In addition, we confirmed our results 
using chemical inhibitors blocking the SFK activity. Lastly, we sought to 
identify the mechanisms by which SFKs affects TLR-mediated pDC 
activation. 
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3. Materials and Methods 
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3.1 Animals 
Wild type (WT) C57Bl/6 and Fyn-/- mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Lyn-/- were a gift from Dr. Kawakami T. (La 
Jolla Institute for Allergy and Immunology, San Diego, CA). Mice were bred 
and maintained in a closed breeding facility, and mouse handling complied 
with the requirements of the National Institutes of Health and the 
Institutional Animal Care and Use Guidelines of the University of California 
San Diego. Six- to ten-week-old mice were used for the experiments. 
3.2 Cell purification 
Murine spleen were incubated with Collagenase D (1mg/mL, Roche, 
Indianapolis, IN) for 20 min at 37°C, passed through a 100 μm strainer in 
order to obtain a single cell suspension, and subsequently FACS purified 
using a BD ARIA (BD Biosciences, San Jose, CA) for B cells (CD19+), T 
cells (Thy1.2+), macrophages (Thy1.2-CD19-NK1.1-CD11c-CD11b+), pDCs 
(Thy1.2-CD19-NK1.1-CD11c+CD11b-B220+PDCA+), and cDCs (Thy1.2-
CD19-NK1.1- and CD11c+B220-CD11b+ or CD11c+B220-CD8+). 
Bone marrow (BM) cells were isolated from femurs and tibias and 
incubated in RPMI with 10% fetal-bovine serum (FBS) (Lonza containing 
100 ng/mL of Flt3L (Amgen, Thousand Oaks, CA) for 8–10 days. At day 8, 
BM-derived DC were FACS purified for pDCs (CD11cintermediate/dimCD11b-
B220+PDCA+), and CD11b+ cDCs (CD11c+B220-CD11b+CD8-). Purity for all 
cell types was >95%. 
3.3 Primary human cells 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole 
blood obtained from healthy volunteers using Ficoll-Paque PLUS (GE 
Healthcare). The UCSD Institutional Review Board approved study 
participants, protocols, and consent forms, and informed consent was 
32 
 
obtained from all participants. 
3.4 Culture and cell line maintenance 
CAL-1 cell line was cultured in RPMI 1640 (Lonza, Walkersville, MD, USA), 
supplemented with 2 mM l-glutamine, 50 U/mL penicillin and 50 μg/mL 
streptomycin (from Gibco, Grand Island, NY, USA), plus 10% heat-
inactivated FBS (Lonza). LYN-deficient CAL-1 were generated by 
CRISPR/Cas9-mediated genome engineering following the protocol 
described by Ran et al. [133]. A target sequence in the fourth exon of 
human LYN (GTAGCCTTGTACCCCTATGATGG (PAM motif underlined) 
was chosen and appropriate oligonucleotides were cloned into the BbsI site 
of pSpCas9(BB)-2A-GFP plasmid obtained from the laboratory of Feng 
Zhang via Addgene (Cambridge, MA; plasmid ID: 48138). The plasmid was 
introduced into CAL-1 using the Amaxa human monocyte nucleofector kit 
(Amaxa), and one day later the GFP positive population was single cell 
sorted into 96-well plate, in order to obtain clonal populations. Cells were 
maintained in 175 cm2 flasks at a density of 1–2 x106 cells/mL in a total 
volume of 30 mL. 
3.5 Nucleic acid isolation, reverse transcription and real-
time quantitative PCR 
Cell lines or primary purified cells were harvested in lysis buffer (Qiagen, 
Valencia, CA). RNA was purified using RNeasy extraction kits with a 
DNase (Qiagen) incubation step to digest any trace genomic DNA present. 
For RNA extraction from cell line lysates, 5 x 105 cells were extracted using 
RNeasy mini columns, and for primary cells, 5-10 x 104 cells were lysed 
and extracted using RNeasy micro columns. For standard qPCR analysis of 
relative mRNA expression levels, cDNA was synthesized using SuperScript 
III (Life Technologies, Carlsbad, CA) followed by incubation with RNase H 
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according to the manufacturer’s protocol. All cDNA products were stored at 
-20°C. Quantification of cDNA was performed using SYBR Green PCR Kit 
or Real-Time PCR Detection System (Applied Biosystem, Carlsbad, CA). 
The set of primers used for this study is reported in Appendix A. The 
relative RNA levels were normalized against GAPDH RNA. 
3.6 Cytokine measurements 
For cytokine measurement in culture supernatants, 5 x 104 FACS-purified 
pDCs, 1 x 105 CAL-1 or 3 x 106 peripheral blood mononuclear cells were 
pre-treated for 1 hour with the SFKs inhibitor PP2 (Calbiochem), the 
inhibitor Bafetinib (Adooq) or the equivalent concentration of DMSO control, 
followed by 15 hours in media in presence or absence of 0.1 μM CpG-B 
ODN 1668, 100 μM loxoribine (murine cells) or 1 mg/mL R848 (human 
cells) (all from InvivoGen). Murine IFN-I bioactivity was measured with 
reference to a recombinant mouse IFN-β standard (Research Diagnostics, 
Concord, MA) using a L-929 cell line transfected with an interferon-
sensitive luciferase. Human IFN-I bioactivity was measured with reference 
to a recombinant human IFN-β standard (InvivoGen) using HEK-Blue™ 
IFN-α/β cell line (InvivoGen). Murine and human TNF-α were measured in 
culture supernatants by ELISA (Mouse TNF alpha ELISA Ready-SET-Go!, 
eBioscience, and Human TNF-alpha ELISA MAX, Biolegend, respectively) 
as described in the manufacturer’s protocol. 
3.7 Flow cytometry 
Prior to staining all cell preparations were blocked with either anti-mouse or 
anti-human CD16/CD32 (Fc block, BD PharMingen) in PBS containing 1% 
FBS for 10 min. For surface staining, cells were stained with saturating 
concentrations of the chosen antibodies in PBS containing 1% FBS for 30 
min at 4°C. For intracellular cytokine staining, cells were stimulated at 37°C 
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for 6 hours and Brefeldin-A (10ng/mL) was added during the last four 4 
hours. The staining was performed in the presence of 0.01% of saponin in 
order to permeabilize the cell membrane. For phosflow staining, the cells 
were fixed with BD Phosflow Lyse/Fix Buffer 5x for 10 minutes at 37°C, and 
then permeabilized with BD Phosflow Perm Buffer III for intracellular 
staining with Abs for phospho-proteins. Cells were acquired using the 
Digital LSR II flow cytometer (Becton Dickinson, San Jose, CA). Flow 
cytometric data were analyzed with the FlowJo software (Treestar, Inc., 
Ashland, OR). Surface marker and intracellular proteins were analyzed on 
viable cells by LIVE/DEAD® fixable aqua dead cell staining (Invitrogen). 
The set of antibodies used for this study is reported in Appendix B. 
3.8 Cell lysates, immunoprecipitation and immunoblotting 
CAL-1 cells were pre-treated with either bafetinib or DMSO control for 1 
hours, stimulated with R848 (1 μg/mL) and subsequently lysed with either 
immunoprecipitation lysis buffer (Thermo Scientific) added with protease 
inhibitor cocktail set III (Calbiochem), phosphatase inhibitor cocktail set I 
and II (Calbiochem) or RIPA buffer (Thermo Scientific) added with protease 
inhibitor cocktail set III (Calbiochem). For immunoprecipitation, 1 mg of 
each lysate were incubated on a rotator for 1 hours at 4°C with the 
appropriate amount of the respective antibody. 30 μL of Protein G 
Sepharose Fast Flow (Sigma) were added, followed by 2 hours incubation 
on a rotator at 4°C, and were recovered with an equal amount of 4x 
laemmli sample buffer (Bio-Rad) containing 2-ME. Proteins were resolved 
by 8, 10, 12% SDS-PAGE, were electrophoretically transferred to PVDF 
membranes (EMD Millipore) and blocked with 3% BSA, 5% BSA or 5% 
non-fat dry milk (according to the primary antibody) in Tris-buffered saline 
containing 0.1% Tween-20; they were then probed with the desired primary 
antibody and an appropriate HRP-conjugated antibody and eventually 
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visualized by ECL Plus (Thermo Scientific). When necessary, membranes 
were stripped using Restore Plus Western Blot Stripping Solution (Thermo 
Scientific).  
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4. Results 
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4.14 SFKs are expressed in murine pDCs and in a human 
pDC cell line 
SFKs play an important role in the regulation of the immune response and 
therefore they are widely expressed through the immune system 
populations. Every immune cell type shows a particular SFK pattern, which 
is used to generate a cell type-specific response to encountered stimuli. Up 
to now, SFK expression in pDCs has been assessed only for few members, 
such as Lyn and Fyn [36,134], therefore we decided to assess the mRNA 
expression levels of all the SFKs in murine and human pDCs and to 
compare them with other murine naïve immune subsets and human 
immune system-derived cell lines, in order to outline the pDC SFK pattern. 
Blk, Lck, Src and Yes were expressed at very low levels in both splenic and 
BM-derived murine pDCs, whereas Fgr, Fyn, Hck and Lyn were the 
members mainly expressed (Figure 4.1a). Intriguingly, murine pDC Fyn 
expression was several folds higher than any other cell types, suggesting 
that this kinase may be important for pDC function. 
To assess the SFKs expression in human pDCs we exploited CAL-1 cells, 
a recently established [135], but already broadly used [15,43], human pDC 
cell line (Figure 4.1b). Similar to murine pDCs, CAL-1 cells showed a low 
expression of BLK and SRC and no detectable expression of LCK and 
YES. Furthemore, unlike murine pDCs, FGR and HCK were poorly 
expressed. Also FYN showed a low expression, although this was not 
surprising since it has already been reported that FYN is poorly expressed 
by human pDCs [36,134]. Finally, the mRNA levels of LYN were notable. 
In conclusion, this data allowed us to outline the pDC SFK expression 
pattern and showed that Fyn and LYN are the SFK members mainly 
expressed by murine and human pDCs.  
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Figure 4.1: SFK expression in murine subsets and human cell lines. 
(Figure continue on next page) 
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Figure 4.1: SFK expression in murine subsets and human cell lines. 
(Legend on next page) 
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The expression of SFK mRNA was assessed by SYBR Green qPCR and it was normalized 
against the expression of GAPDH. A: Murine WT splenic mononuclear cells (SMCs) were 
FACS-purified for B cells (CD19+), T cells (Thy1.2+), macrophages (Thy1.2-CD19-NK1.1-
CD11c-CD11b+), pDCs (Thy1.2-CD19-NK1.1-CD11c+CD11b-B220+PDCA+), and cDCs 
(Thy1.2-CD19-NK1.1- and CD11c+B220-CD11b+ or CD11c+B220-CD8+), followed by total 
mRNA extraction. Bone marrow from WT mice was cultured in Flt3L containing media for 
eight days and then FACS-purified for pDCs (CD11c+CD11b-B220+PDCA+) and cDCs 
(CD11c+CD11b+B220-), followed by total mRNA extraction. B: Cells from human cell lines 
were collected before reaching confluency and then total mRNA were extracted. A549: lung 
epithelial cell line; CAL-1: human pDC cell line; Jurkat: T cell line; Ramos: B cell line; THP-1: 
monocyte cell line. 
4.2 SFKs are necessary to fully drive the cytokine 
production by murine pDCs 
Confirming a significant expression of SFKs by pDCs, we subsequently 
evaluated whether they play a role in the pDC ability to sense and respond 
to invading pathogens. To answer this question, we treated BM-derived 
pDCs with PP2, a pan-SFK inhibitor, in order to inhibit simultaneously all 
the family members and to elude the grade of complexity due to the 
redundant activity among the SFKs, a common practice within this family. 
Intriguingly, the drug was able to decrease in a dose-dependent manner 
the IFN-I and TNFα production by BM-derived pDCs stimulated either with 
CpG-B, a TLR9 agonist, or Loxoribine, a TLR7 agonist, without affecting 
the viability of the cells (Figure 4.2a), proving that the activity of SFKs is 
necessary to drive the pDC response after TLR stimulation. However, 
considered the broad spectrum of action of PP2, this treatment did not 
allow us to attribute this defect in the cytokine production by pDCs to any 
single or group of SFKs. Since it has been proposed many times that pDCs 
exploit a BCR-like pathway [36,134,136], which involved Blk and Lyn as 
SFKs, and given that murine pDCs showed a very low Blk expression, we 
decided to investigate whether Lyn was the SFK necessary for the pDC 
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activation. As hypothesized, we observed a reduced production of IFN-I 
after CpG-B and Loxoribine stimulation and of TNFα after CpG-B 
stimulation by BM-derived pDCs from Lyn-/- mice compared to those from 
their WT littermate (Figure 4.2b). Conversely, no defect was observed in 
the cytokine production by cDCs, although a small increase in the TNFα 
production after TLR7 stimulation was observed (Figure 4.2c). To overrule 
the hypothesis that the pDC reduced cytokine production was caused by a 
developmental defect, we quantified the relative frequencies of pDCs and 
cDCs after 8 days of cultivation in presence of Flt3L, and we did not 
observed any difference in terms of relative frequencies (Figure 4.2d). 
However, the Lyn deficiency did not totally ablate the IFN-I production as 
the PP2 administration did, suggesting a redundancy with other SFKs. 
Although not involved in the BCR-like pathway, Fyn was the SFK most 
impressively expressed by murine pDCs, thereby we hypothesized its 
involvement in pDC activation. Consistently with our hypothesis, BM-
derived pDCs from Fyn-/- mice stimulated with either Loxoribine or CpG-B 
showed generally at least a 50% reduction in the production of IFN-I and 
TNFα compared to WT BM-derived pDCs (Figure 4.2e). Additionally, this 
defect was restricted to the pDCs population, since cDCs did not show any 
impairment in the cytokine production (Figure 4.2f). Eventually, as for Lyn-/- 
pDCs, we did not observe any developmental defect (Figure 4.2g). 
 
Figure 4.2: SFKs are necessary to fully drive the cytokine production by 
murine pDCs. 
(Figure continue on next page) 
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Figure 4.2: SFKs are necessary to fully drive the cytokine production by 
murine pDCs. 
(Legend on next page) 
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A: Bone marrow-derived DCs were pre-treated for 1 hr with SFKs inhibitor PP2, or the 
equivalent concentration of DMSO control, followed by 15 hrs in media in presence or 
absence of 0.1 μM CpG-B ODN 1668. Supernatants were collected and IFN-I was 
measured by an interferon sensitive luciferase reporter bioassay, and TNF-α was measured 
by ELISA. Cell viability was assessed by live/death staining and analyzed by FACS. (B-F) 
Bone marrow from WT and Lyn
-/-
 (B-D) or WT and Fyn
-/-
 (E-G) mice was cultured in Flt3L 
containing media for eight days prior harvest and FACS-purification of pDCs and CD11b
+
 
cDCs. B, E: Sample FACS plot showing pre-FACS purification viability, distribution of DC 
subsets and sort gating strategy. C, D, F, G: FACS-purified pDCs (C, F) and cDCs (D, G) 
were cultured 15 hrs in media alone or stimulated with either 100 μM loxoribine (loxo) or 0.1 
μM CpG-B ODN 1668. Supernatants were collected and IFN-I were measured by an 
interferon sensitive luciferase reporter bioassay, and TNF-α was measured by ELISA. White 
bar: WT mice; Black bar: KO mouse. Graphs show mean ± SD of n≥3/group and 
representative of 2-4 independent experiments. * p<0.05, ** p<0.01, ***p<0.001. 
Taken together, our data showed that SFKs are necessary for cytokine 
production by murine pDCs after TLR stimulation, and that both Lyn and 
Fyn are involved, playing a partially redundant role. 
4.3 SFKs positively regulate the activation of a human 
pDC cell line after TLR stimulation 
To elucidate whether human pDCs require SFKs to promote the TLR-
induced immune response, we evaluated IFN-I and TNFα production by the 
human pDC cell line stimulated with R848, a TLR7/8 agonist, after 
treatment with the pan-SFK inhibitor. Consistently with the murine data, the 
treatment caused a reduction in the TLR-induced CAL-1 cytokine 
production, in the absence of any effects on cell viability (Figure 4.3a). 
With the purpose to narrow the SFK requirement to the kinases effectively 
involved, we restricted our attention to the SFK implicated in the BCR-like 
signaling and the ones we have already observed to be required for the 
murine pDC activation. Considering that BLK and FYN mRNAs seem 
expressed at negligible levels, we focused on LYN, and we established a 
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LYN-/- CAL-1 cell line (Figure 4.3b). We observed that the absence of LYN 
profoundly affects the IFN-β mRNA synthesis after TLR7 stimulation 
(Figure 4.3c). However, IFN-I was still detectable, although significantly 
reduced (Figure 4.3d), suggesting that also in CAL-1 there is a partial 
functional redundancy among SFKs. 
Considering its peculiar ability to inhibit only some members of the SFKs, 
restriction hypothesized to be dictated by the requirement to have 
determined aminoacids in specific position of the ATP-binding site in the 
kinase domain, we decided to assess whether the selective dual ABL/LYN 
inhibitor bafetinib was capable of altering CAL-1 activation [137]. 
Interestingly, bafetinib was able to strongly inhibit in a dose-dependent 
manner the IFN-I production by CAL-1 after R848 stimulation without 
affecting cell viability (Figure 4.3e). In addition, a reduction in the TNFα 
production was also observed (Figure 4.3e). 
 
Figure 4.3: SFKs regulate positively the activation of a human pDC cell line 
after TLR stimulation. 
(Figure continue on next page) 
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Figure 4.3: SFKs regulate positively the activation of a human pDC cell line 
after TLR stimulation. 
A, B: Human pDC cell line CAL-1 pre-treated for 1 hr with either the SFKs inhibitor PP2 (A) 
or the dual inhibitor ABL/LYN bafetinib (B), or the equivalent concentration of DMSO control 
followed by 15 hrs in media in presence or absence of R848 (1mg/mL). Supernatants were 
collected and IFN-I was measured by an interferon sensitive luciferase reporter bioassay, 
and TNF-α was measured by ELISA. Cell viability was assessed by live/death staining and 
analyzed by FACS. C: Whole-cell lysates were prepared and resolved proteins were probed 
with antibodies against LYN and GAPDH. D, E: Cells were cultivated in presence of 
absence of 1 mg/mL R848 for 1 hour (D) or 15 hours (E). D: total mRNAs were extracted 
and the expression of IFN-β mRNA was assessed by SYBR Green qPCR and it was 
normalized against the expression of GAPDH. The graph represents the IFN-β mRNA fold 
increase after 1 hour stimulation. E: IFN-I production was measured by an interferon 
sensitive luciferase reporter bioassay Graphs show mean ± SD of 3-5 independent 
experiments. * p<0.05, ** p<0.01, ***p<0.001.  
B 
C D 
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4.4 Bafetinib decreases the TLR pathway activation in a 
pDC cell line 
TLR7 and 9 signal through similar pathways, which involve the 
phosphorylation or ubiquitination of kinases and adaptor proteins and end 
up with the activation of several transcription factors, including NF-κB, AP-1 
and IRF7 [19]. To evaluate how the SFK activity influences this pathway, 
we stimulated bafetinib-treated CAL-1 cells with R848 and we analyzed the 
phosphorylation of different kinases downstream TLR7 by western blot and 
flow cytometry. We opted for bafetinib instead of PP2 since it proved to be 
more efficient to turn off the cytokine production. CAL-1 treated cells 
showed a slighter increase in the phosphorylation associated with the 
activation of IKKα/β, the kinase complex which leads NF-κB activation, 
mitogen-activated protein kinases ERK1/2 and P38, indicating a milder 
initiation of the TLR7 pathway (Figures 4.4a and 4.4b). 
However, IFN-I can be produced by pDCs not only in response to TLR 
stimulation. Indeed, its production is also strongly driven by a positive 
feedback loop, in which the IFN-I produced early after TLR stimulation acts 
in an autocrine way binding the IFN-I receptors (IFNAR) present on the 
same cell and stimulating the transcription of new IFN-I and IFN-stimulated 
genes [28]. To assess an involvement of SFKs also in this pathway, we 
stimulated bafetinib-treated CAL-1 with different amounts of IFN-β. 
Interestingly, no difference in STAT1 phosphorylation, the main 
transcription factor downstream the IFNAR, were observed compared to 
the control-treated cells (Figures 4.4c), suggesting that SFKs are not 
involved in the IFNAR mediated IFN-I production. 
Taken together, these data showed that SFKs are necessary to drive a 
complete TLR7 pathway activation. 
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Figure 4.4: Bafetinib decreases the activation of several key signaling 
mediators downstream TLR stimulation. 
A: CAL-1 cells were pre-treated for 1 hr with Bafetinib, or the equivalent concentration of 
DMSO control, and stimulated with R848 (1 mg/mL). Whole-cell lysates were prepared and  
 (Legend continue on next page)  
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resolved proteins were probed with antibodies against phopsho-IKK α/β (p-IKKα/β), IKKα/β, 
phopsho-ERK1/2 (p-ERK1/2), ERK1/2. B: cells were treated and stimulated as in A, directly 
fixed, subsequently methanol-permeabilized and stained with phospho-P38 (p-P38) 
antibody. The line graph shows the phosphorylation kinetic of P38 after stimulation. The 
histogram bar depicts a representative timepoint (15 minutes). Black line: DMSO control 
treated. Red line: Bafetinib treated. C: cells were treated as in A and stimulated with either 
1000 or 200 U/mL of INF-I, directly fixed, subsequently methanol-permeabilized and stained 
with phospho-STAT1 (p-STAT1) antibody. The line graph shows the phosphorylation kinetic 
of STAT1 after stimulation. The histogram bars depict a representative timepoint (15 
minutes). Graphs show mean ± SD of 2-3 independent experiments. * p<0.05, ** p<0.01, 
***p<0.001. 
4.5 Bafetinib affects PI3K-AKT-MTOR pathway and the 
adaptor protein BCAP 
Recent discoveries have revealed the value of PI3K [50] and MTOR [51] for 
pDC IFN-I production, raising the importance of the PI3K-AKT-MTOR 
pathway within the pDC biology. Considering this, we decided to assess the 
MTOR activation kinetic after TLR7 stimulation in the presence of bafetinib. 
The treatment caused a reduction in the activating phosphorylation of 
MTOR, starting at 15 minutes and lasting for all the timepoints considered, 
suggesting that the SFK activity is necessary to lead to the MTOR 
activation (Figure 4.5a). However, the dynamics that bring SFKs to 
influence MTOR are not clear. Recently, two studies have identified B-cell 
adapter for phosphoinositide 3-kinase (also known as BCAP or PIK3AP1) 
as the protein connecting the PI3K-AKT-MTOR pathway to the TLR 
pathway [54,55]. This is an adaptor protein capable of interacting with 
MYD88, through a Toll-IL-1 receptor (TIR) domain, and with the regulatory 
subunit of PI3K, through a YxxM motif which acts as docking site for the 
PI3K Src-homology 2 (SH2) domain after phosphorylation. Which kinase 
phosphorylates BCAP is still unclear, and different studies have proposed a 
role for Lyn, Syk and Btk [55]. To assess whether SFKs are involved in this 
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phosphorylation in pDCs, we immunoprecipitated BCAP from either 
bafetinib- or control-treated CAL-1 which were kept unstimulated or were 
stimulated for 15 minutes with R848 and we performed western blotting to 
detect tyrosine phosphorylation. At the level of the BCAP molecular weight, 
the anti-phosphorylated tyrosine antibody detected a lower intensity when 
the cells were treated with the drug. Interestingly, this alteration was 
already present before the TLR stimulation (Figure 4.5b). These data 
suggest that SFKs are involved in BCAP phosphorylation and that 
upstream signals causing BCAP tyrosine phosphorylation are active in 
resting pDCs. 
 
 
Figure 4.5: Bafetinib affects PI3K-AKT-MTOR pathway and the adaptor 
protein BCAP. 
 (Legend continue on next page)  
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A: CAL-1 cells were pre-treated for 1 hr with Bafetinib, or the equivalent concentration of 
DMSO control, and stimulated with R848 (1 mg/mL) for different time. Cells were directly 
fixed, subsequently methanol-permeabilized and stained for phospho-MTOR (p-MTOR). B: 
BCAP was immunoprecipitated from CAL-1 cells either unstimulated or stimulated for 15 
minutes with R848 and probed with antibodies to phosphotyrosine or BCAP. p-Tyr: 
antibodies to phosphotyrosine. Graphs show mean ± SD of 2-4 independent experiments. * 
p<0.05, ** p<0.01, ***p<0.001. 
4.6 SFKs are needed for complete IFN-I and TNF-α 
production after TLR stimulation by primary human PBMCs 
To investigate the potential biological and clinical relevance of the 
observation noted above in the murine and in vitro model system, we 
determined whether the inhibition of SFK activity by PP2 or bafetinib can 
block the pDC activation after engagement of TLR by R848. Consistently, 
PP2-treated R848-stimulated peripheral blood mononuclear cells (PBMCs) 
from healthy donors showed a decreased production of IFN-I and TNF-α 
production despite any effect of the drug on the cell viability (Figure 4.6a). 
Intriguingly, bafetinib showed a deeper abolition of the cytokine production 
compared to PP2 (Figure 4.6b). To assess more precisely the effect of 
Bafetinib on pDCs in the PBMC mixed culture, we exploited flow cytometry 
to perform a per-cell analysis (Figure 4.6c). The bafetinib treatment caused 
a dose dependent decrease in the percentage of positive IFN-I and TNF-α 
pDCs, and, in addition to this, it caused also a decrease in the MFI of the 
positive populations, indicating that the response to TLR stimulation is 
smaller both in term of number and strength (Figure 4.6d). Moreover, we 
also confirmed that pDCs were the only source of IFN-I after 6 hours of 
R848 stimulation (data not shown), confirming that the decreased IFN-I 
production observed in the supernatant of the PBMC mixed culture was 
attributable to the bafetinib effect on pDCs. 
These data suggested that SFK activity was necessary to drive a complete 
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cytokine production by pDCs derived from healthy donor after TLR7 
stimulation. 
 
 
Figure 4.6: Bafetinib affects IFN-I and TNF-α production of primary human 
PBMCs. 
(Figure continue on next page) 
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Figure 4.6: Bafetinib affects IFN-I and TNF-α production of primary human 
PBMCs. 
Human peripheral blood mononuclear cells were pre-treated for 1 hr with either PP2 (A) or 
Bafetinib (B), or the equivalent concentration of DMSO control, followed by 15 hrs in media 
in presence or absence of R848 (1mg/mL). Supernatants were collected and IFN-I was 
measured by an interferon sensitive luciferase reporter bioassay, and TNF-α was measured 
by ELISA. Cell viability was assessed by live/death staining and analyzed by FACS. C, D: 
Human peripheral blood mononuclear cells were pre-treated for 1 hr with Bafetinib, or the 
equivalent concentration of DMSO control, followed by 6 hrs in media in presence or 
absence of either R848 (1 mg/mL). C: Sample FACS plot showing IFN-α and TNF-α 
expression in pDCS. D: IFN-α and TNF-α MFI of pDC IFN-α and TNF-α positive population. 
Graphs show mean ± SD of n≥2/group and representative of 2-4 independent experiments 
and n=4 human samples. * p<0.05, ** p<0.01, ***p<0.001 
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5. Discussion 
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pDCs are a subset of dendritic cells able to produce prodigious amounts of 
IFN-I after recognition of pathogen associated molecular patterns through 
TLR7 and TLR9, which lead to the activation of IRF-7, with subsequent 
production of IFN-I, and of NF-κB, with production of pro-inflammatory 
cytokines such as TNF-α. A fine tuning of this process is necessary, since a 
deregulated production of IFN-I can cause immunopathologies. Indeed 
systemic lupus erythematosus (SLE) has been associated with an IFN-I 
signature, and recently it has been demonstrated in murine models that 
pDC-produced IFN-I is one of the key elements driving SLE [79,80]. 
Instead, in the context of viral infection, the initial peak of IFN-I production 
seems to be required for a quick resolution of the infection, whereas the 
continuous low IFN-I production after the peak seems to favor the viral 
persistence [68,69]. Several receptors on the surface of pDCs modulate 
their cytokine production and, although the downstream pathway that they 
activate is still unclear, it has been shown that often it starts from an 
immunoreceptor tyrosine-based activation motif or immunoreceptor 
tyrosine-based inhibition motif. Given that phosphorylation of ITAM and 
ITIM motifs is often mediated by SFKs, a family of non-receptor tyrosine 
kinases, we decided to investigate the role of SFKs in pDCs biology. 
At first, we confirmed at the mRNA level the SFK expression by murine 
pDCs and the human pDC cell line CAL-1, and we observed that the 
different members of the family are not all represented at the same degree. 
In mouse, the transcript level of Blk, Lck, Src and Yes were very low, 
suggesting that they are not primarily involved in the pDC biology. Instead, 
Fgr, Fyn, Hck and Lyn were the SFKs mainly expressed, with Fgr, Fyn and 
Lyn at a degree similar to or higher than any other immune cell types 
analyzed. Intriguingly, Fyn expression in murine pDCs was by several folds 
the highest among the immune subsets considered, suggesting an 
importance for this kinase in the murine pDC biology. In contrast, no SFKs 
were expressed at outstanding levels in CAL-1 cells compared to the other 
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human immune system-derived cell lines, and only LYN expression could 
be considered noteworthy. However, CAL-1 cells well resembled human 
blood-derived primary pDCs: indeed, previous studies showed that human 
pDCs express low BLK and FYN and high LYN both at the mRNA and 
protein level [36,134]. 
Interestingly, the SFKs play a role in the pDC biology, and they are 
necessary for the complete pDC activation after TLR stimulation. The 
administration of the pan-SFK inhibitor PP2 on murine pDCs showed that 
their activity is necessary to the full IFN-I and TNFα production after 
stimulation of TLR7 and TLR9. Taking advantage of murine genetic model 
of single SFK deletion, we tried to individuate the family members involved. 
At first, we identified the involvement of Lyn, thereby confirming the 
hypothesis that pDCs exploit a BCR-like signaling [36,134,136]. However, 
the inflammatory mediator production was not completely ablated, 
suggesting that other family members were playing a role. But since the 
other kinase usually associated with the BCR signaling is Blk and given that 
we detected a low Blk mRNA expression by murine pDCs, we instead 
decided to evaluate Fyn, which showed to be the SFK most impressively 
expressed by murine pDCs at the mRNA level. Consistently with our 
hypothesis, pDCs from Fyn-/- mice showed generally at least a 50% 
reduction in the production of IFN-I and TNFα compared to WT pDCs. 
Since the absence of neither Lyn nor Fyn was enough to totally ablate the 
pro-inflammatory cytokine production, we hypothesized a partial functional 
redundancy among the SFKs. Also human pDCs require SFK activity to 
fully drive the inflammatory mediator production after TLR stimulation. 
Indeed, the treatment of CAL-1 cells and human blood-derived primary 
pDCs with the pan-SFK inhibitor PP2 resulted in a lower IFN-I and TNFα 
secretion. Exploiting the CRISPR-Cas9 technology, we observed that the 
absence of LYN negatively impacted the human pDC response to TLR 
stimulation. Again, the deletion of LYN alone was not sufficient to totally 
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ablate the CAL-1 response to R848, suggesting that also in CAL-1 several 
SFKs exert a partially redundant role. 
To further investigate the involvement of SFKs in the pDC biology, we 
decided to take advantage of the selective dual ABL/LYN inhibitor bafetinib 
[137]. A kinase inhibition profile, in which 79 tyrosine kinases were tested, 
showed that bafetinib, at the concentration of 0.1 μM, was able to inhibit 
almost totally the activity of ABL, ABL-related gene (ARG) and LYN [137]. 
In addition, it also inhibited more than 75% of the FYN activity and almost 
50% of the BLK activity. Instead, it was not able to inhibit SRC and YES, 
the other SFKs tested, thereby showing different affinities for the different 
family members. We administered bafetinib to CAL-1 and human blood-
derived primary pDCs and, intriguingly, we observed a strong reduction in 
IFN-I and TNFα production, even more profound than that observed with 
the PP2 treatment. This difference in the effects between these two 
compounds could be explained by the fact that bafetinib seems to be a 
better LYN inhibitor, and indeed its IC50 (the half maximal inhibitory 
concentration, or IC50, is a measure of how effective a drug is, and it 
indicates how much of a particular drug is needed to inhibit a given 
biological process, as an enzyme, by half) for LYN is 19 nM [137]. Although 
the PP2 IC50 for LYN has not been reported yet [138], its IC50 for LCK, the 
SFK bound with more affinity, is only 30-40 nM [139,140]. In addition, a 
recent study performed an ATP-site competition binding assay on several 
tyrosine kinases using 10 μM of PP2 and it showed that LYN was still 
retaining 10% of its activity [141]. Another explanation of the more profound 
effect seen with the administration of bafetinib could be connected with the 
ABL activity. However, pDCs derived from the peripheral blood of chronic 
myeloid leukemia patients treated with imatinib, a selective ABL inhibitor, 
showed IFN-α production after ex-vivo HSV stimulation higher than those of 
chronic myeloid leukemia patients refractory to bafetinib treatment and 
similar to those of healthy donors [142]. In addition, it has been reported 
58 
 
several times that also PP2 is able to inhibit ABL activity, and already at the 
concentration of 2 μM (as assessed in an in vitro kinase assay) [141,143]. 
These last observations lead us to speculate that the stronger inhibition 
seen with the administration of bafetinib is not related to ABL activity, 
although we know that further investigation are necessary to definitively 
rule out this scenario. 
In conclusion, we exploited different inhibitors and several murine and 
human genetic models of SFK deletion to prove that SFKs activity is 
necessary to drive the full IFN-I and pro-inflammatory cytokine production 
after TLR stimulation by pDCs. However, how the SFK activity is necessary 
for the TLR-mediated pDC activation is not known. 
To address this question, we performed several experiments to shed light 
on the mechanisms behind this phenotype. We decided to use bafetinib 
instead of PP2, since it has been shown to inhibit more profoundly the TLR-
mediated activation. In addition, several studies pointed out that PP2 is not 
as selective as previously believed, and several off-target kinases (as ABL, 
CSK, CK1δ, P38) can be inhibited already at low drug concentration 
[97,140]. We observed that bafetinib administration reduced the TLR-
mediated activating phosphorylation of P38, IKKα/β and ERK1/2, some of 
the main kinases downstream of TLR7 [19]. In contrast, the treatment did 
not cause any difference in STAT1 activating phosphorylation level after 
IFN-β stimulation, suggesting that SFKs affect pDC activation through the 
regulation of the TLR receptor pathway and not of the positive feedback 
loop driven by the autocrine action of the IFN-I produced early after 
stimulation [28]. In addition, we observed that TLR7-mediated stimulation of 
CAL-1 lead to increased activation of MTOR, and that bafetinib was able to 
inhibit this process, thereby furthermore influencing the pro-inflammatory 
cytokine production [51]. We hypothesized that the reduced MTOR 
activation could be the consequence of a defective recruitment of PI3K by 
TLR, since we observed a diminution of the tyrosine phosphorylation level 
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of BCAP, an adaptor protein that links TLRs to PI3K-AKT-MTOR pathway 
binding the PI3K SH2 domain with a phosphorylated tyrosine and bringing 
the phosphatidylinositol bisphosphate kinase near the activated TLRs and, 
subsequently, near its substrate [54,55]. Eventually, we observed that 
bafetinib was affecting BCAP tyrosine phosphorylation level also in the 
absence of TLR stimulation, leading us to speculate about the SFKs 
involvement in a tonic signal necessary to place the pDCs in a ready-to-
respond state, a pre-condition necessary to respond to external stimulation. 
The need of a basal signaling tuning the cellular response to external 
stimulation has been already theorized and confirmed for many other 
immune cell types, and it always involved immunoreceptors and kinases 
belonging to either the Src-family or the Syk-family, as we hypothesized for 
pDCs [144–146]. 
Taken together, our data showed that SFKs are key elements involved in 
the tuning of the pDC activation after pathogen recognition by the 
intracellular TLRs, and considering that has been shown that pDCs play 
important roles in the defense against pathogens, tumor immune-
surveillance and autoimmune disease, SFK activity manipulation holds 
great promise for immune-based therapeutics to attenuate several human 
illnesses. 
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6. Conclusion 
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Plasmacytoid dendritic cells are the most powerful interferon type I (IFN-I) 
producers among the immune cell subsets. In order to avoid a dysregulated 
production that could lead to immunopathologies, they exploit the activity of 
several surface receptors, which mainly signal through ITIM and ITAM, to 
modulate their activation status. Given that phosphorylation of ITAM and 
ITIM is often mediated by SFKs, a family of non-receptor tyrosine kinases, 
we decided to investigate the role of SFKs in pDCs biology. 
At first, we showed that pDCs express a particular SFK expression pattern, 
different from the other immune subsets, and that Fyn and LYN were the 
SFK members mainly expressed by murine and human pDCs. Then, we 
showed that SFKs were required to induce pDC activation after TLR-
stimulation, and that Fyn, in mouse, and Lyn, in both human and mouse, 
were involved. However, since the single deletion of these genes did not 
totally ablate the IFN-I and TNFα production, we hypothesized that several 
members of the family play a partial redundant activity. To test this 
hypothesis, we will assess the pDC activity in murine genetic models of 
double or triple gene deletion and we will perform a siRNA matrix on the 
human pDC cell line to silence more kinases at the same time. 
Furthermore, we showed that the absence of the SFK activity diminished 
the activation of several kinases and transcription factors downstream the 
TLR pathway, such as IKKα/β, ERK1/2, P38 and IRF7, and that also MTOR 
activation was affected by SFK action, likely as consequence of the BCAP 
tyrosine phosphorylation, which is an adaptor protein that bridges TLR and 
PI3K-AKT-MTOR pathways. To understand which elements upstream 
SFKs regulate their activity, we have planned to immunoprecipitate several 
ITAM- and ITIM-bearing receptors in either presence or absence of SFK 
inhibitors and to evaluate their tyrosine phosphorylation status. 
Lastly, we showed that inhibitors of SFK activity are able to affect pDC IFN-
I and TNFα production during in vitro and ex vivo experiments. These 
intriguing results let us to suggest a possible clinical use of SFKs inhibitors 
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to attenuate pDC response in autoimmune diseases, although we are 
aware that further in vivo studies will be necessary. 
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8.1 Appendix A 
Primer used in the study: 
 Primer Forward Primer Reverse 
Murine 
Blk 
AAGCCACTGAAGCTGACTGAGA TCACTGACCTGCCTCTTGCTG 
Human 
BLK 
CCTGCTCCACTGTAAGGGTG TCCATTGGCCCTTGTCCTTC 
Murine 
Fgr 
AGATCCGAAAGCTGGACACG AGAGTCTGGGGCTTAGTGGT 
Human 
FGR 
CCGGAAAAACTGGCTGCATT GGTCTCGCTTTCCCGAATGA 
Murine 
Fyn 
AAGCACGGACGGAAGATGAC ATGGAGTCAACTGGAGCCAC 
Human 
FYN 
ACAGCTCGGAAGGAGATTGG CTGTCGCTCAGCATCTTTTCG 
Murine 
Hck 
GGCACGAATCATCGAGGACA GTAAGGGATCCGGCCATAG 
Human 
HCK 
CCATCAAGTGGACAGCTCCT AGCTCGGATCACTTCAGGGT 
Murine 
Lck 
TGGGACCTTCACCATCAAGTC TGTCAGGTCTCACCATGCG 
Human 
LCK 
TCCTGCTGACGGAAATTGTCA CACACTGCGCAGGTAGTCA 
Murine 
Lyn 
TGGCTAAGGGTAGTTTGCTGG CGCAGATCACGGTGGATGTA 
Human 
LYN 
ACCAGGGAGGAGCCCATTTA CTTCCGCTCGATGTATGCCA 
Murine 
Src 
GCCTCACTACCGTATGTCC TTTTGATGGCAACCCTCGTG 
Human 
SRC 
GCTGTTCGGAGGCTTCAACT CCAGTCTCCCTCTGTGTTGT 
Murine 
Yes 
TGAGGCTGCTCTGTATGGTC GCATTCTGTATCCCCGCTCT 
Human 
YES 
GCTGCACTGTATGGTCGGTT TCCTGTATCCTCGCTCCACT 
Human 
IFN-β 
AAACTCATGAGCAGTCTGCA AGGAGATCTTCAGTTTCGGAGG 
Human 
TNF-α 
ACCCACACCATCAGCCGCAT TGGCCAGAACCAAAGGCTCCCT 
82 
 
 
  
Human 
GAPD
H 
TGATGACATCAAGAAGGTGGTGA
AG 
TCCTTGGAGGCCATGTGGGCCAT 
Murine 
Gapdh 
TCCCACTCTTCCACCTTCGA AGTTGGGATAGGGCCTCTCTT 
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8.2 Appendix B 
Antibodies used in the study 
For flow cytometry the following antibodies were used: anti-mouse Thy1.2 
(clone 30-H12), anti-mouse CD11c (N418), anti-mouse B220 (RA3-6B2), 
anti-mouse CD8a (53-6.7), anti-human CD3 (UCHT1), anti-human CD14 
(HCD14), anti-human CD16 (3G8), anti-human CD19 (HIB19), anti-human 
CD56 (MEME-188), anti-human CD11c (3.9), anti-human CD123 (6H6), 
anti-human CD304 (12C2), anti-human HLA-DR (L243), anti-human TNF-α 
(Mab11) from Biolegend; anti-mouse CD19 (eBio1D3), anti-mouse NK1.1 
(PK136), anti-mouse CD11b (M1/70), anti-mouse CD317 (eBio927), anti-
human p-MTOR (MRRBY) from eBioscience; anti-human p-STAT1 
(612564) from BD Biosciences; anti-human p-IRF7 (REA310) and anti-
human IFN-α (LT27:295) from Miltenyi Biotec; anti-human p-P38 (D3F9) 
from Cell Signaling Technology. 
For immunoprecipitation and for immunoblotting the following antibodies 
were used: anti-human p-ERK1/2 (9101S) and anti-human p-IKKα/β 
(2694P) from Cell Signaling Technology; anti-human ERK1/2 (5AD13MA) 
from eBioscience; anti-human IKKα/β (sc-7607) from Santa Cruz 
Biotechnology; anti-human LYN (LYN-01) from Biolegend; anti-human 
PIK3AP1 (ab157151) from Abcam; anti-phospho tyrosine (4G10) from EMD 
Millipore. 
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